Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
1 mg
5 mg
10 mg
1 mM
2.0937 mL
10.4686 mL
20.9371 mL
5 mM
0.4187 mL
2.0937 mL
4.1874 mL
10 mM
0.2094 mL
1.0469 mL
2.0937 mL
50 mM
0.0419 mL
0.2094 mL
0.4187 mL
Description
TRx 0237 mesylate (LMTX, Hydromethylthionine) is a second-generation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia.
TRx 0237 (LMTX™) is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia. It is a purified forms of Methylene Blue, an old drug that predates the FDA and is being widely used in Africa for the treatment for malaria as well as for methemoglobinemia and other conditions. An in vitro study showed the ability of TRx 0237 in disrupting PHFs(paired helical filaments) isolated from Alzheimer's Disease brain tissues at the concentration at 0.16 μM.
In vivo
TRx 0237 dose-dependently rescues the learning impairment and restores behavioral flexibility in a spatial problem-solving water-maze task in L1 (minimum effective dose: 9 mg MT/kg for TRx0237) and correctes motor learning in L66 (effective doses: 4 mg MT/kg). It reduces the number of tau-reactive neurons, particularly in the hippocampus and entorhinal cortex in L1 and in a more widespread manner in L66.
